A Phase 3 interventional study of Golimumab and Placebo in Arthritis, Rheumatoid, sponsored by Centocor, Inc.. Completed at 91 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-25.
Sponsored by Centocor, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing golimumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. golimumab · Arthritis, Rheumatoid.
Among the 16 studies testing golimumab in Arthritis, Rheumatoid, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 11 in phase 3, and was the 8th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 16 studies testing golimumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
golimumab: first FDA approval 2009 (SIMPONI), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 592 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 356 across the 16 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 8 most frequent:
This study is registered under Centocor, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Centocor, Inc. is the lead sponsor of 75 studies on the registry; none are open to participants now.
90 studies in Arthritis, Rheumatoid by Johnson & Johnson: 1 open now, 1 under way, none of them phase 3. Of 86 finished, 31 (36%) have results posted.
Among the 90 studies in Arthritis, Rheumatoid by Johnson & Johnson, this one is the 10th largest by enrollment of the 75 interventional ones that give a count, is one of 4 that started in 2009, is one of 20 in phase 3, and was the 51st registered.
Johnson & Johnson’s Arthritis, Rheumatoid studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing golimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 90 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate clinical effectiveness and safety of golimumab with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) when compared to MTX alone.
This is a randomized (study medication is assigned by chance), double-blind (neither physician nor participants knows the treatment that the participant receives), placebo-controlled (an inactive substance is compared with a medication to test whether the medication has a real effect in a clinical study), multicenter, 2-arm (2 groups) study of golimumab in participants with active RA despite concurrent MTX therapy. Approximately 564 participants will be randomly allocated to 1 of 2 treatment groups in a 2:1 ratio ie, Group 1(approximately 376 participants will receive golimumab + MTX) and Group 2 (approximately 188 participants will receive MTX + placebo). Total duration of study for each participant is 112 weeks. Safety will be evaluated by assessment of adverse events, tuberculosis testing and blood testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo at Weeks 0, 4, 12, and 16. Participants will cross over to golimumab at Week 24, and receive administrations at Weeks 24, 28, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will be eligible for early escape (receive golimumab) at Week 16 if they demonstrate a less than 10 percent improvement in both tender and swollen joint count. These participants will receive golimumab at Weeks 16, 20, and every 8 weeks thereafter.
Drug: Golimumab · Other: Placebo · Drug: methotrexate (MTX)
Participants will receive golimumab at Weeks 0, 4, and every 8 weeks thereafter. They will be maintained on their stable dose of commercial methotrexate throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.
Drug: Golimumab · Other: Placebo · Drug: methotrexate (MTX)
Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14
An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 20 percentage improvement in at least 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS), (0 \[no pain\] to 10 \[worst pain\]) b. Participant's global assessment of disease activity by VAS c. Physician's global assessment of disease activity by VAS d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C-reactive protein.
Time frame: Week 14
Proportion of Participants With Moderate or Good Response in Disease Activity Index Score 28 (DAS28) Using C-reactive Protein (CRP) at Week 14
DAS28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis combining tender joints (28 joints), swollen joints (28 joints), CRP, and participant's global assessment of disease activity. The DAS28 score ranges from 0 (best) to 10 (worst). DAS28 score above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. Higher scores indicate worsening. A decrease in DAS28 score \>1.2 is being referred to as a "good response" and a decrease of 0.6-1.2 as a "moderate response".
Time frame: Week 14
Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14
The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). HAQscore on a scale ranges from 0 (no disability) to 3 (completely disabled). Higher scores indicate worsening.
Time frame: Week 14
Proportion of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24
An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm) b. Participant's global assessment of disease activity by VAS (0-10 cm) c. Physician's global assessment of disease activity by VAS (0-10 cm) d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.
Time frame: Week 24
Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24.
Total vdH-S score is sum of joint erosion score and joint-space narrowing (JSN) score. Joint erosion score summarizes erosion severity in 32 joints of hands and 12 joints of feet. Each joint scored from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Maximal erosion score is 280. JSN score summarizes severity of JSN in 30 joints of hands and 12 joints of feet. Assessment of JSN, including subluxation, is scored from 0 (normal) to 4 (bony ankylosis or complete luxation). Maximal JSN score is 168. Thus, the worst possible vdH-S score is 448.
Time frame: Week 24
This study evaluated the efficacy and safety of intravenous administration of Golimumab 2mg/kg + methotrexate (MTX) in patients with Active Rheumatoid Arthritis despite treatment with MTX therapy. It was conducted between 14 September 2009 and 08 February 2013 and recruited participants at 92 sites in 13 countries worldwide.
| Milestone | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) |
|---|---|---|
| Started | 197 | 395 |
| Completed | 160 | 326 |
| Not completed | 37 | 69 |
| Withdrew: Lost to follow-up | 0 | 3 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Withdrawal by subject | 15 | 16 |
| Withdrew: Lack of efficacy | 5 | 7 |
| Withdrew: Adverse event | 12 | 32 |
| Withdrew: Protocol violation | 2 | 2 |
| Withdrew: Other | 1 | 7 |
An ACR 20 response is defined as a greater than or equal to 20 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 20 percentage improvement in at least 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS), (0 \[no pain\] to 10 \[worst pain\]) b. Participant's global assessment of disease activity by VAS c. Physician's global assessment of disease activity by VAS d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C-reactive protein.
| Percentage of Participants | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) |
|---|---|---|
| Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14 | 24.9 | 58.5 |
DAS28 using CRP is an index to measure the disease activity in participants with rheumatoid arthritis combining tender joints (28 joints), swollen joints (28 joints), CRP, and participant's global assessment of disease activity. The DAS28 score ranges from 0 (best) to 10 (worst). DAS28 score above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. Higher scores indicate worsening. A decrease in DAS28 score \>1.2 is being referred to as a "good response" and a decrease of 0.6-1.2 as a "moderate response".
| Percentage of Participants | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) |
|---|---|---|
| Proportion of Participants With Moderate or Good Response in Disease Activity Index Score 28 (DAS28) Using C-reactive Protein (CRP) at Week 14 | 40.1 | 81.3 |
The HAQ is 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty), to 3 (inability to perform a task in that area). HAQscore on a scale ranges from 0 (no disability) to 3 (completely disabled). Higher scores indicate worsening.
| Scores on a scale | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire (HAQ) Score at Week 14 | 0.1250 ± 0.55770 | 0.5000 ± 0.57706 |
An ACR 50 response is defined as a greater than or equal to 50 percent improvement from baseline in: 1. Swollen (66 joints) and tender (68 joints) joint counts; 2. greater than or equal to 50 percentage improvement in 3 of the following 5 assessments: a. Participant's assessment of pain by Visual Analog Scale (VAS) (0-10 cm) b. Participant's global assessment of disease activity by VAS (0-10 cm) c. Physician's global assessment of disease activity by VAS (0-10 cm) d. Participant's assessment of physical function as measured by the Health Assessment Questionnaire (HAQ) e. C reactive protein.
| Percentage of Participants | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) |
|---|---|---|
| Proportion of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24 | 13.2 | 34.9 |
Total vdH-S score is sum of joint erosion score and joint-space narrowing (JSN) score. Joint erosion score summarizes erosion severity in 32 joints of hands and 12 joints of feet. Each joint scored from 0 (no erosion) to 5 (extensive loss of bone from more than one half of the articulating bone). Maximal erosion score is 280. JSN score summarizes severity of JSN in 30 joints of hands and 12 joints of feet. Assessment of JSN, including subluxation, is scored from 0 (normal) to 4 (bony ankylosis or complete luxation). Maximal JSN score is 168. Thus, the worst possible vdH-S score is 448.
| Scores on a scale | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) |
|---|---|---|
| Change From Baseline in Total Van Der Heijde Modified Sharp (vdH-S) Score at Week 24. | 1.09 ± 3.194 | 0.03 ± 1.899 |
Collected over Adverse events data were collected for the duration of study (100 weeks) and follow-up (12 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 16 | — | 11/68 (16.2%) | 34/68 (50%) |
| Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 24 | — | 17/121 (14%) | 38/121 (31.4%) |
| Golimumab 2 mg/kg + MTX | — | 78/395 (19.7%) | 199/395 (50.4%) |
| Combined Golimumab | — | 106/584 (18.2%) | 271/584 (46.4%) |
| Event | Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 16 | Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 24 | Golimumab 2 mg/kg + MTX | Combined Golimumab |
|---|---|---|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 2/68 | 0/121 | 10/395 | 12/584 |
| Angina pectorisCardiac disorders | 1/68 | 0/121 | 1/395 | 2/584 |
| Atrial fibrillationCardiac disorders | 1/68 | 0/121 | 1/395 | 2/584 |
| Myocardial infarctionCardiac disorders | 1/68 | 0/121 | 1/395 | 2/584 |
| Sick sinus syndromeCardiac disorders | 1/68 | 0/121 | 0/395 | 1/584 |
| Device related infectionInfections and infestations | 1/68 | 0/121 | 0/395 | 1/584 |
| EndophthalmitisInfections and infestations | 1/68 | 0/121 | 0/395 | 1/584 |
| PneumoniaInfections and infestations | 1/68 | 0/121 | 4/395 | 5/584 |
| ConcussionInjury, poisoning and procedural complications | 1/68 | 0/121 | 0/395 | 1/584 |
| ContusionInjury, poisoning and procedural complications | 1/68 | 0/121 | 0/395 | 1/584 |
| Event | Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 16 | Placebo + MTX -> Golimumab 2 mg/kg + MTX at Week 24 | Golimumab 2 mg/kg + MTX | Combined Golimumab |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/68 | 8/121 | 54/395 | 67/584 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 9/68 | 3/121 | 33/395 | 45/584 |
| Alanine aminotransferase increasedInvestigations | 8/68 | 3/121 | 27/395 | 38/584 |
| HypertensionVascular disorders | 8/68 | 4/121 | 27/395 | 39/584 |
| BronchitisInfections and infestations | 6/68 | 9/121 | 37/395 | 52/584 |
| Aspartate aminotransferase increasedInvestigations | 5/68 | 2/121 | 18/395 | 25/584 |
| HeadacheNervous system disorders | 5/68 | 2/121 | 27/395 | 34/584 |
| NasopharyngitisInfections and infestations | 3/68 | 8/121 | 28/395 | 39/584 |
| PharyngitisInfections and infestations | 0/68 | 7/121 | 26/395 | 33/584 |
| Urinary tract infectionInfections and infestations | 3/68 | 7/121 | 26/395 | 36/584 |
| Age, Continuous(years) | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) | Total |
|---|---|---|---|
| Mean | 51.4 ± 11.26 | 51.9 ± 12.55 | 51.8 ± 12.13 |
| Sex: Female, Male(Participants) | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) | Total |
|---|---|---|---|
| Female | 157 | 326 | 483 |
| Male | 40 | 69 | 109 |
| Region of Enrollment(participants) | Group I: Placebo + Methotrexate (MTX) | Group II: Golimumab 2 mg/kg + Methotrexate (MTX) | Total |
|---|---|---|---|
| Argentina | 28 | 54 | 82 |
| Australia | 3 | 6 | 9 |
| Columbia | 12 | 25 | 37 |
| Hungary | 10 | 21 | 31 |
| Korea, Republic of | 4 | 12 | 16 |
| Lithuania | 20 | 44 | 64 |
| Malaysia | 8 | 18 | 26 |
| Mexico | 13 | 25 | 38 |
| New Zealand | 2 | 4 | 6 |
| Poland | 36 | 65 | 101 |
| Russian Federation | 23 | 46 | 69 |
| Ukraine | 32 | 58 | 90 |
| United States | 6 | 17 | 23 |
The record gives a start of Sep 2009, a primary completion of Mar 2011 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2013, 2 years 7 months after primary completion. A results delay was requested in Mar 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Golimumab · Methotrexate